Arbutus Biopharma (ABUS) Other Operating Expenses (2013 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Other Operating Expenses of $209000.0 for Q1 2026, down 30.1% year-on-year from $299000.0 in Q1 2025, and up 107.87% on a QoQ basis from -$2.7 million in Q4 2025.
Arbutus Biopharma (ABUS) Other Operating Expenses (2013 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Other Operating Expenses for 13 consecutive years, with $209000.0 the latest figure, recorded in Q1 2026.
- Quarterly Other Operating Expenses fell 30.1% year-over-year to $209000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.2 million (down 615.85% YoY) and the FY2025 annual result came in at $674000.0, changed N/A from the prior year.
- Other Operating Expenses grew to $209000.0 in Q1 2026 per ABUS's latest filing, from -$2.7 million in the prior quarter.
- Over the last five years, Other Operating Expenses for ABUS reached as high as $1.9 million in Q4 2024 and fell as low as -$12.0 million in Q2 2025.
- A 5-year average of -$525235.3 and a median of $211000.0 in 2024 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2022 — Other Operating Expenses surged 733.68% — and 2025, when it sank 5775.36%.
- Year by year, Other Operating Expenses stood at $1.6 million in 2022, then sank by 85.89% to $227000.0 in 2023, then surged by 732.6% to $1.9 million in 2024, then sank by 240.58% to -$2.7 million in 2025, then soared by 107.87% to $209000.0 in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $209000.0, -$2.7 million, and $268000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209,000.00 |
| Dec 31, 2025 | -2.66 Mn |
| Sep 30, 2025 | 268,000.00 |
| Jun 30, 2025 | -11.98 Mn |
| Mar 31, 2025 | 299,000.00 |
| Dec 31, 2024 | 1.89 Mn |
| Sep 30, 2024 | 344,000.00 |
| Jun 30, 2024 | 211,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Sep 30, 2023 | 205,000.00 |
| Jun 30, 2023 | -636,000.00 |
| Mar 31, 2023 | 273,000.00 |
| Dec 31, 2022 | 1.61 Mn |
| Sep 30, 2022 | 215,000.00 |
| Jun 30, 2022 | 208,000.00 |
| Mar 31, 2022 | 201,000.00 |
| Dec 31, 2021 | 193,000.00 |
| Sep 30, 2021 | 856,000.00 |
| Jun 30, 2021 | 694,000.00 |